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A B S T R A C T
To evaluate the efﬁcacy and safety of gamma knife radiosurgery (GKS) in treating temporal lobe epilepsy,
GKS was performed in four adult patients with recurrent complex partial seizures who underwent
incomplete anterior temporal lobectomy (ATL) but were reluctant to undergo a second resective surgery.
A marginal dose of 24.5–25 Gy, corresponding to 65–70% isodose curve, was delivered to the treatment
target that included the residual amygdala and the head and anterior body of the hippocampus.
None of the patients had severe acute side effects but three patients had radiation-inducedMRI signal
changes around the target volume 13, 20, and 24 months after GKS, respectively. All four patients had
signiﬁcant seizure reduction during the ﬁrst 6-month period and clinical efﬁcacy persisted throughout
the 2-year follow-up period. All of the patients also had improved neuropsychological proﬁles, including
memory function and quality-of-life, compared to their pre-GKS conditions.
In conclusion, the safety and clinical efﬁcacy of GKS make it a reasonable and suitable therapeutic
alternative for patients with recurrent seizures after incomplete ATL. A higher marginal dose of >25 Gy
and wider coverage may be more clinically beneﬁcial but warrant further investigation.
 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Gamma knife radiosurgery (GKS) has been successfully used in
the treatment of mesial temporal lobe epilepsy (MTLE) and
epileptic seizures caused by difﬁcult-to-access lesions, including
intracerebral tumors, arteriovenous malformations, cavernous
hemangioma, and hypothalamic harmatomas.1–8
In a multi-center European study enrolling 21 patients with
MTLE indicated for temporal lobectomy, 13 patients were
seizure-free for 2 years after GKS treatment.1 In addition, there
was no neuropsychological deterioration in these patients.1 The
results were encouraging and were comparable to those
achieved by conventional standard anterior temporal lobectomy
(ATL) or selective amygdalo-hippocampectomy.9 After >5 years
of follow-up, 9 out of 16 patients remained seizure-free.7* Corresponding author at: 201, Sec. 2, Shi-pai Rd, Shi-pai, Taipei 11217, Taiwan,
ROC. Tel.: +886 2 28757581; fax: +886 2 28757581.
E-mail address: djyen@vghtpe.gov.tw (D.-J. Yen).
1059-1311/$ – see front matter  2009 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2009.05.005Disadvantages of GKS for the treatment of MTLE, nonetheless,
included acute or chronic post-irradiation side effects due to a
large target volume; also, signiﬁcant seizure reduction was
usually delayed, e.g., 9–12 months after GKS.1,7 Regarding
irradiation dose, a marginal dose at 24  1 Gy appeared much
more effective than using a low dose (15–24 Gy), as reported in
previous studies.1,7,10–13
In this prospective study, we enrolled patients with recurrent
habitual complex partial seizures after incomplete ATL. Instead
of reoperation, GKS was performed targeting solely the residual
amygdalar and hippocampal tissues in each of the patients. To
our knowledge, this target approach has not been reported
previously.
2. Materials and methods
The database consisted of 324 patients who underwent
standard ATL for the treatment of medically intractable MTLE;
these patients were followed up at Taipei Veterans General
Hospital between January 1, 1990 and December 31, 2004. Eligiblevier Ltd. All rights reserved.
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secondary generalization, residual mesial temporal structures in
MRI, no new postoperative EEG focus, and reluctance to undergo
reoperation (further resective surgery).
Using a Leksell gamma knife, standard radiosurgical lesioning
was performed on the target volume. In this study, the target
volume was determined and delineated in cooperation with
neurosurgeon and neuroradiologist, and included residual amyg-
dala and the head and anterior body of the hippocampus. The
marginal dose was set at approximately 25 Gy. In addition, careful
protection of surrounding critical structures was ensured to keep
radiation doses to the optic apparatus and to brainstem below
12 Gy and 15 Gy, respectively.
All patients were discharged with pre-existing antiepileptic
drugs (AEDs) after GKS and were then followed at the outpatient
seizure clinic. In the event of initial worsening of seizures, the
neurologist in charge could increase the dose of pre-existing
AEDs, using short-term treatment with a benzodiazepam
like clobazam or midzolam, or add another AED in cases of
cluster seizures or status epilepticus. Seizure frequency and
adverse events were recorded in a seizure diary issued by
Taiwan Epilepsy Society. In this study, we included in the
analysis only complex partial seizures with or without
secondary generalization and excluded ‘‘auras’’ or simple partial
seizures.
Serial MRIs were conducted in all patients for the detection of
any remarkable radiation-induced signal changes on target.
Neuropsychological assessments including memory function
(Weschler Memory Scale-III, face and word list subtests),
intelligent quotient (IQ), and quality-of-life questionnaire were
performed prior to and 2 years after GKS.
This study was approved by the Institutional Review Board and
Ethics Committee of Taipei Veterans General Hospital. All patients
gave consent forms.
3. Results
Clinical data from the four patients who received GKS
treatment are shown in Table 1. All four patients were females,
24–39 years of age and 3–15 years after ATL; twowere previously
operated on the right side and two on the left side. We haveTable 1
Clinical data of the patients undergone gamma knife radiosurgery (GKS).
Patient #1
Age/sex 39/F
Years after temporal lobectomy 15
Side of surgery and pathology Rt/gliosis
Residual temporal structures A,H,P
Volume of residual structure (ml) 1.6
Volume of GKS radiation (ml) 2.4
GKS dose (Gy), 65–70% isodose 25 (65%)
Coverage of lesions 99%
Dose at target center (Gy) 38.46
Mean Dose (Gy) 31
MRI signal changes; month after GKS 20
Number of seizuresa
6 months before GKS 25
1–6 months after GKS 11
7–12 months after GKS 7
13–18 months after GKS 11
19–24 months after GKS 18
Weschler Memory Scale-III
Face subtest (pre-GKS/after GKS) 18/20
Word list subtest (pre-GKS/after GKS) 25/32
GKS, gamma knife radiosurgery; Rt, right; Lt, left; A, amygdala; H, hippocampus; P, pa
a Complex partial seizures.excluded three other patients; onewho respondeddramatically to
a new AED add-on and two who insisted on AED treatment only.
MRI (Fig. 1A) demonstrated residual mesial temporal structures
including the amygdala, the head and anterior body of the
hippocampus, and parahippocampal gyrus in one of the patients
(#1).
The marginal dose of GKS was 24.5–25 Gy in the patients in
this study, corresponding to the 65–70% isodose curve; the
mean dose ranged from 30 Gy to 31.2 Gy. The target volume was
2.4–3.8 ml, with 96–99% coverage of lesions, including residual
amygdala and the head and anterior body of the hippocampus
(Fig. 2).
All patients were discharged on the day following GKS. At the
ﬁrst 2-week outpatient visit, no patients reported severe acute side
effects, which would indicate increased intracranial pressure
(IICP). During the initial visits throughout the ﬁrst 6 months, there
was no initial worsening of seizures, and no status epilepticus
occurred in any of the patients during the 2-year follow-up period.
Routine blood cell count and serum biochemistry follow-ups were
within the normal range in all patients.
With respect to seizure control, signiﬁcant seizure reduction
was found following the ﬁrst 6-month period after GKS
(Table 1). Though none of the patients became seizure-free, a
28.0–66.7% seizure reduction rate compared with that before
GKS was achieved during the ﬁnal 6-month period of the 2-year
follow-up. Based on the average number of seizures per month,
three patients (#1, #3, and #4) experienced >50% seizure
reduction throughout the 2-year follow-up period. Seizure
reduction did not correlate well with the occurrence of
radiation-induced signal changes in the MRI; these changes
occurred 13, 20, and 24 months after GKS, respectively, in three
patients (Fig. 1B). All three of these patients tolerated the MRI
signal changes and/or swelling well, and none required
corticosteroid treatment. One patient (#2) underwent reopera-
tion to remove residual mesial temporal structures after the 2-
year follow-up period.
The Weschler Memory Scale follow-up at 2-year post-GKS
showed improved scores compared to those achieved before GKS
in all the patents. Three patients improved >6 points in the non-
verbal face recognition subtest and three patients improved
signiﬁcantly in verbal word list recall and recognition subtests#2 #3 #4
28/F 24/F 30/F
3 5 10
Rt/gliosis Lt/gliosis Lt/gliosis
A,H,P H A
2.1 1.1 1.7
3.2 3.3 3.8
25 (65%) 24.5 (65%) 25 (70%)
96% 98% 97%
38.46 37.69 35.71
31.1 31.2 30
24 Nil 13
21 180 9
13 66 1
23 91 4
12 72 5
13 114 3
15/22 4/13 15/27
18/31 3/4 22/34
rahippocampal gyrus.
Fig. 1. Coronal T2-weighted images of MR (TR/TE/NEX 4000/100/4) showing focal
tissue loss (arrow) and residual hippocampal body on the right side (arrowhead)
before GKS (A). Radiation-induced signal changes are noted (arrows) after GKS (B).
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IQ and three patients were stable. On quality-of-life question-
naires, all patients had better scores after GKS.
4. Discussion
In this study reporting results with four patients, GKS appears
to be effective in the treatment of recurrent seizures after
incomplete ATL. By comparison, reoperations were performed
among <4.7% of patients after temporal lobe resection for the
treatment of epilepsy in Montreal Neurological Institute.14
Though seizure-free or ‘‘having rare seizures’’ outcomes were
achieved in 45–63% of patients after reoperation, the risk ofsurgical morbidity and cost for re-evaluation must be consid-
ered.14,15 Finally, GKS does not exclude future reoperation; one of
our patients and one patient of Bartolomei et al.7 underwent
reoperation with favorable seizure control after unsatisfactory
GKS.
In comparison with earlier reports,1,7 we found no initial
worsening of seizures in any of the patients after GKS. In addition,
after the earlier follow-up periods, a notable seizure reduction was
found that persisted throughout the 2-year period, though none of
the patients became seizure-free. In contrast to previous studies,
only complex partial seizures were included in the analysis of
recurrences in the present study. Our rationale for this is that
impairment of consciousness is quite disabling for the patients and
can lead to unexpected injury or mortality, whereas the auras or
simple partial seizures which patients experienced were either
variable or non-speciﬁc and could usually be tolerated. Other
clinical beneﬁts of GKS identiﬁed in this study include improved
neuropsychological proﬁles, including memory function and
quality-of-life.
In this study, seizure control in patients was not as promising
as that suggested by previous studies in MTLE patients who had
not received prior surgical treatment.1,7 We proposed the
following hypothesis to explain the result. First, a marginal dose
of 24.5–25 Gy at 65–70% isodose curve, i.e., a maximal isocenter
dose at 35.7–38.5 Gy, or a mean dose at 30–31.2 Gy, may be
inadequate. The low marginal dose may also be reﬂected in the
observed delayed occurrence of radiation-induced MRI signal
changes in our patients, 13–24 months vs. the more usual 9–12
months after GKS.1,7 In addition, none of our patients experienced
severe acute post-irradiation side effects after GKS or developed
apparent IICP symptoms such as headache, while radiation-
induced MRI signal changes, which required corticosteroid
treatment, occurred in approximately 60% of patients in the
previous studies.1,7 Second, our coverage of lesions mimicking a
GKS-induced selective amygdalo-hippocampectomy may be too
limited. Indeed, while delineating the target volume, the
possibility of using a wider coverage including the entire residual
mesial temporal structures and the parahippocampal gyrus was
considered. However, due to a concern as to whether GKS might
induce a severe cerebral edema in patients who had undergone
ATL and in order to maximize protection of nearby brainstem and
optic tracts, we chose a restrictive but seemingly safe target
volume.
The third possible reason for the somewhat lower effectiveness
of GKS observed in the present study compared to other studies
relates to postoperative changes. One hypothesis of how focal
irradiation acts to reduce seizures is that, since neurons are more
radio-resistant than supporting structures, neuronal damage in the
epileptogenic focus is caused by ischemia due to vascular
inﬂammation.8 In our patients, advanced scar formation in the
treated areas and subsequent shrinkage of vasculature due to
previous ATL might have negatively affected neuronal response to
GKS. Fourth, in any of our patients, the epileptogenic focus might
have been located outside of the mesial temporal structures. This
concern seems less compelling, since all patients had congruent
data indicating MTLE during presurgical evaluation, which
included continuous video-EEG monitoring, MRI and positron
emission tomography. In addition, none of the patients developed
new EEG foci after ATL.
In conclusion, the safety and clinical efﬁcacy of GKS demon-
strated in this study show that GKS is a reasonable and suitable
therapeutic alternative for patients with recurrent seizures after
incomplete ATL who are psychologically or physically not
indicated for reoperation. The optimal GKS technical parameters
for these patients, including target dose and volume, deserve
further study.
Fig. 2. Stereotactic MR imaging performed for localization of target volume and radiosurgical dose planning. These ﬁgures show radiosurgical target volume (magenta line),
including the residual amygdala and the hippocampus, covered by yellow line (25 Gy marginal dose). Blue line indicates the optic apparatus. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of the article.)
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